Revenues: Total revenue was $60.0 million for the third quarter of 2020 compared to $92.0 million for the third quarter of 2019. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including the timing and content of advice given and decisions made by health authorities, including approval and labeling decisions; the actual time it takes to make regulatory submissions for vadadustat to health authorities, including the submission of the NDA to the FDA and the submission of the MAA to the EMA; risks associated with the Priority Review Voucher for vadadustat; the potential direct or indirect impact of the COVID-19 pandemic on our business, operations, and the markets and communities in which we and our partners, collaborators, vendors and customers operate; manufacturing and quality risks; risks associated with management and key personnel changes and transitional periods; the actual funding required to continue to commercialize our commercial product, to develop and commercialize vadadustat, and to operate the Company; market acceptance and coverage and reimbursement of our commercial product and vadadustat, if approved; the risks associated with potential generic entrants for our commercial product and vadadustat, if approved; early termination of any of Akebia's collaborations; Akebia's and its collaborators' ability to satisfy their obligations under Akebia's collaboration agreements; the competitive landscape for our commercial product and vadadustat; the scope, timing, and outcome of any legal, regulatory and administrative proceedings; changes in the economic and financial conditions of the businesses of Akebia and its collaborations partners and vendors; and Akebia's ability to obtain, maintain and enforce patent and other intellectual property protection for our commercial product, vadadustat and any other product candidates. The insider ownership for the shares of Akebia … Créanciers Commerciaux. DSE-US-0063. This compares to year-ago revenues of $91.98 million. Obtenez le compte de résultat trimestriel/annuel détaillé de AKEBIA THERAPEUT.DL-00001 (AX9.F). Comprenez le tableau de financement de AKEBIA THERAPEUT.DL-00001 (AX9.F), découvrez l’origine des fonds et les dépenses de la société. Recherchez les prévisions de marché, les actualités financières et du marché concernant AKBA. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. All rights reserved. A replay of the conference call will be available two hours after the completion of the call through November 11, 2020. These data were clear and consistent, and showed that vadadustat achieved both the primary and key secondary efficacy endpoints, as well as the primary and key secondary safety endpoints of the program for patients on dialysis. Akebia's revenue grew 21,724% during the period from 2016 to 2019. Anemia due to CKD can have a profound impact on a person's quality of life as it can cause fatigue, dizziness, shortness of breath and cognitive dysfunction. Le Chiffre D'Affaires De Vente. While Akebia Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? earnings-and-revenue-growth. A key component of this NDA is the positive data from our global Phase 3 INNO2VATE program for the treatment of anemia due to CKD in adult patients on dialysis, which we shared most recently at ASN Kidney Week. If you do not, click Cancel. Following the recent earnings report, the consensus from eight analysts covering Akebia Therapeutics is for revenues … ", Butler continued, "The pre-NDA meeting also allowed us the opportunity to clarify key questions regarding data from PRO2TECT, our global Phase 3 program for the treatment of anemia due to CKD in adult patients not on dialysis, and we look forward to working with the FDA in their review of these data. Ahead of this earnings release, the estimate revisions trend for Akebia Therapeutics was mixed. The call will also be webcast LIVE and can be accessed via the Investors section of the Company's website at Start here. Consultez le graphique AKEBIA THERAPEUTICS INC en direct pour suivre l'évolution des cours de ses actions. In addition, Akebia and its collaborator, Otsuka Pharmaceutical Co. Ltd., are working in close collaboration to prepare a Marketing Authorization Application (MAA) for submission to the European Medicines Agency (EMA) next year. Akebia Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $90.14 million for the quarter ended June 2020, surpassing the Zacks Consensus Estimate by 18.24%. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. It specializes in the development of digital platforms for digital media companies, cloud and managed service providers, financial institutions, and telecommunications providers. Too much information and not sure what to do? Zacks Equity Research If you wish to go to ZacksTrade, click OK. Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ November 16, 2020. CAMBRIDGE, Mass. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Following the downgrade, the consensus from eight analysts covering Akebia Therapeutics is for revenues of US$240m in 2021, implying a concerning 22% decline in … Vadadustat is Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) in development for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis and not on dialysis. Visit to get our data and content for your mobile app or website. The decline versus the prior year period was driven by lower collaboration revenue consistent with the Company completing the INNO 2 VATE and PRO 2 TECT studies. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the bottom 25% of the 250 plus Zacks industries. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Akebia Therapeutics, Inc. … This was an important milestone for our vadadustat development program, and we remain on track to submit an NDA to the FDA as early as possible next year. The monthly returns are then compounded to arrive at the annual return. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 2860285. About VadadustatVadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. Investor Contact:Kristen K. Sheppard,, (in thousands, except share and per share data), Weighted-average number of common shares - basic and diluted, Cash, cash equivalents and available for sale securities, View original content to download multimedia:, Akebia Therapeutics, Inc. The company has topped consensus revenue estimates two times over the last four quarters. Top Research Reports for Amazon, Alphabet & Zoom Video, 5 Sector ETFs that Beat the Market in November. Akebia Therapeutics 's estimated annual revenue is currently $235M per year. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.